Author + information
- Iwan Harries, MBBCha,
- Kate Liang, MBBCha,
- Matthew Williams, MBChBa,
- Bostjan Berlot, MDa,b,
- Giovanni Biglino, PhDa,c,
- Patrizio Lancellotti, MD, PhDd,e,
- Juan Carlos Plana, MDf@juancplana and
- Chiara Bucciarelli-Ducci, MD, PhDa,∗ (, )@chiarabd
- aBristol Heart Institute, Bristol National Institute of Health Research (NIHR) Biomedical Research Centre, University Hospitals Bristol NHS Trust and University of Bristol. Bristol, United Kingdom
- bDepartment of Cardiology, University Medical Centre Ljubljana, Slovenia
- cNational Heart and Lung Institute, Imperial College London, London, United Kingdom
- dUniversity of Liège Hospital, GIGA Cardiovascular Sciences, Departments of Cardiology, Heart Valve Clinic, CHU Sart Tilman, Liège, Belgium
- eGruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy
- fTexas Heart Institute at Baylor St. Luke’s Medical Center, Baylor College of Medicine, Houston, Texas
- ↵∗Address for correspondence:
Dr. Chiara Bucciarelli-Ducci, Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Upper Maudlin Street, Bristol BS2 8HW, United Kingdom.
• Cancer therapy improves cancer survival but can result in a variety of cardiovascular toxicities.
• Cardiovascular magnetic resonance is an extremely versatile and useful tool to assess cardiovascular toxicities of cancer therapy.
• Technological improvement, collaboration, research, and education are essential to the evolving use of cardiovascular magnetic resonance in cardio-oncology.
This paper aims to empower and inform cardio-oncologists by providing a practical guide to the clinical application of cardiac magnetic resonance (CMR) in the rapidly evolving field of cardio-oncology. Specifically, we describe how CMR can be used to assess the cardiovascular effects of cancer therapy. The CMR literature, relevant societal guidelines, indication-specific imaging protocols, and methods to overcome some of the challenges encountered in performing and accessing CMR are reviewed.
- cardiovascular magnetic resonance
- left ventricular dysfunction
- tissue characterization
Dr. Bucciarelli-Ducci is in part supported by the National Institutes of HealthR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health and Social Care. Dr. Bucciarelli-Ducci is the CEO of the Society for Cardiovascular Magnetic Resonance (part-time). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: CardioOncology author instructions page.
- Received December 6, 2019.
- Revision received April 12, 2020.
- Accepted April 15, 2020.
- 2020 The Authors